Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
CompletedPhase 2NCT01725087
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this trial is to evaluate the safety and efficacy of once daily orally administered GRT6005 in a total of 3 fixed doses compared to placebo in subjects with moderate to severe chronic Low Back Pain (LBP). The study includes a maximum of 21 days screening period followed by a 2-week titration period and 12-week maintenance double-blind treatment period and a 10-14 day safety follow up period. Patients who are eligible for the double-blind treatment period will be randomized to one of the following treatment groups: GRT6005 low-dose, GRT6005 medium dose, GRT6005 high-dose, Tapentadol or placebo.
Study details
- Official title
- Efficacy, Safety, and Tolerability of GRT6005 in Subjects With Moderate to Severe Chronic Low Back Pain.
- Conditions
- Interventions
- Drug: Matching Placebo
- Drug: Low Dose GRT6005
- Drug: Medium Dose GRT6005
- Drug: High Dose GRT6005
- Drug: Tapentadol
- Sponsor
- Tris Pharma, Inc.
- Collaborators
- Forest Laboratories
- Start date
- 2012-11
- Primary completion
- 2014-07
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- Austria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
- Total sites listed
- 79
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic Low Back Pain of non-malignant origin and present for at least 3 months. * Signed informed consent. * Pain intensity score of 5 or greater on the 11-point numeric rating scale (where 0 indicates "no pain" and 10 indicates "as bad as you can imagine"). * On stable analgesic medications (non-opioid and/or opioid medications) for chronic low back pain with regular intake for at least 3 months and dissatisfied with current analgesic treatment. Exclusion Criteria: * Female subjects who are pregnant or are breastfeeding. * Presence of risk factors for Torsade de Pointes. * Any clinically significant disease or laboratory findings that may affect efficacy or safety assessments or may compromise the safety during trial participation, e.g., significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders. * History of acute hepatitis within the past 3 months or chronic hepatitis or a positive result on anti-hepatitis A antibody, hepatitis B surface antigen, or anti-hepatitis C antibody. History of human immunodeficiency virus (HIV) infection. * History of seizure disorder. * Chronic low back pain potentially associated with a specific spinal cause. * Surgery or painful procedure during or within 3 months of enrollment. * Conditions that contribute and confound the assessment of pain. * Subjects with impaired renal function. * Subjects with impaired hepatic functionality. * Neuromodulation. * Cancer. * Clinically relevant history of hypersensitivity, allergy or contraindications to any of the Investigational Medicinal Products' excipients, paracetamol/acetaminophen, tapentadol Hydrochloride, or opioid analgesics (or excipients).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01725087